INHIBIKASE THERAPEUTICS INC(NASDAQ:IKT) stock News

IKT Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill - Mentions: CASI XNET ADAP TPIC ...

These stocks are moving in today's pre-market session

7 days ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

7 days ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

7 days ago - By: Benzinga - Mentions: IBIO SNGX LIXT ALTS ...

12 Health Care Stocks Moving In Monday's After-Market Session

8 days ago - By: Benzinga - Mentions: SNGX CASI MTNB ADAP ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

11 days ago - By: The Motley Fool

Inhibikase Posts Wider Loss in Q2

11 days ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

3 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

3 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

4 months ago - By: Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

4 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

5 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

5 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

6 months ago - By: Inhibikase Therapeutics

Inhibikase Announces Expansion of Senior Leadership Team

6 months ago - By: Inhibikase Therapeutics

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

6 months ago - By: Inhibikase Therapeutics

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

9 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

9 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

10 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

10 months ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

a year ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

a year ago - By: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

a year ago - By: InvestorPlace

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024

a year ago - By: BusinessInsider

INHIBIKASE THERAPEUTICS INC (IKT) Stock News

IKT Latest News, Press Relases and Analysis